BR112021019110A2 - Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios - Google Patents
Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatóriosInfo
- Publication number
- BR112021019110A2 BR112021019110A2 BR112021019110A BR112021019110A BR112021019110A2 BR 112021019110 A2 BR112021019110 A2 BR 112021019110A2 BR 112021019110 A BR112021019110 A BR 112021019110A BR 112021019110 A BR112021019110 A BR 112021019110A BR 112021019110 A2 BR112021019110 A2 BR 112021019110A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- pharmaceutical compositions
- inflammatory disorders
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios. a presente invenção refere-se a compostos de acordo com fórmula i: em que r1, r2, r5 e cy são como aqui definidos. a presente invenção refere-se a compostos, métodos para a produção de ditos compostos, composições farmacêuticas compreendendo os ditos compostos e métodos para a profilaxia e/ou tratamento de doenças inflamatórias, doenças autoimunes, dor, fibrose e/ou doenças proliferativas através de administração de ditos compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1904374.4A GB201904374D0 (en) | 2019-03-29 | 2019-03-29 | Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders |
| PCT/EP2020/058063 WO2020200899A1 (en) | 2019-03-29 | 2020-03-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019110A2 true BR112021019110A2 (pt) | 2021-11-30 |
Family
ID=66443107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019110A BR112021019110A2 (pt) | 2019-03-29 | 2020-03-24 | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220194938A1 (pt) |
| EP (1) | EP3947377A1 (pt) |
| JP (1) | JP2022526176A (pt) |
| KR (1) | KR20210143904A (pt) |
| CN (1) | CN113677679A (pt) |
| AU (1) | AU2020254882A1 (pt) |
| BR (1) | BR112021019110A2 (pt) |
| CA (1) | CA3134735A1 (pt) |
| GB (1) | GB201904374D0 (pt) |
| IL (1) | IL286685A (pt) |
| MX (1) | MX2021011575A (pt) |
| SG (1) | SG11202110678UA (pt) |
| WO (1) | WO2020200899A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023098857A1 (zh) * | 2021-12-03 | 2023-06-08 | 武汉人福创新药物研发中心有限公司 | Irak4抑制剂及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418965C (zh) * | 2003-08-15 | 2008-09-17 | 万有制药株式会社 | 咪唑并吡啶衍生物 |
| WO2005108399A1 (ja) * | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
| JP2018524372A (ja) * | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| SG11201810769QA (en) * | 2016-06-01 | 2018-12-28 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
| EP3911652A1 (en) * | 2019-01-18 | 2021-11-24 | Biogen MA Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| GB201904375D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2019
- 2019-03-29 GB GBGB1904374.4A patent/GB201904374D0/en not_active Ceased
-
2020
- 2020-03-24 JP JP2021557760A patent/JP2022526176A/ja active Pending
- 2020-03-24 CN CN202080026691.6A patent/CN113677679A/zh active Pending
- 2020-03-24 US US17/599,471 patent/US20220194938A1/en active Pending
- 2020-03-24 SG SG11202110678UA patent/SG11202110678UA/en unknown
- 2020-03-24 AU AU2020254882A patent/AU2020254882A1/en not_active Abandoned
- 2020-03-24 MX MX2021011575A patent/MX2021011575A/es unknown
- 2020-03-24 CA CA3134735A patent/CA3134735A1/en active Pending
- 2020-03-24 EP EP20715294.3A patent/EP3947377A1/en active Pending
- 2020-03-24 WO PCT/EP2020/058063 patent/WO2020200899A1/en unknown
- 2020-03-24 KR KR1020217035255A patent/KR20210143904A/ko unknown
- 2020-03-24 BR BR112021019110A patent/BR112021019110A2/pt not_active Application Discontinuation
-
2021
- 2021-09-26 IL IL286685A patent/IL286685A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220194938A1 (en) | 2022-06-23 |
| KR20210143904A (ko) | 2021-11-29 |
| WO2020200899A1 (en) | 2020-10-08 |
| SG11202110678UA (en) | 2021-10-28 |
| MX2021011575A (es) | 2021-10-13 |
| CA3134735A1 (en) | 2020-10-08 |
| IL286685A (en) | 2021-10-31 |
| CN113677679A (zh) | 2021-11-19 |
| EP3947377A1 (en) | 2022-02-09 |
| AU2020254882A1 (en) | 2021-11-25 |
| GB201904374D0 (en) | 2019-05-15 |
| JP2022526176A (ja) | 2022-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019055A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| EA202091512A1 (ru) | Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| BR112018067312A2 (pt) | compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose | |
| BR112017006713A2 (pt) | inibidor de egfr, e preparação e aplicação do mesmo | |
| CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| BR112015020998A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112016012734A8 (pt) | composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| PH12018502337A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |